Clinical Trial Update: Study of Omalizumab in Moderate to Severe Bronchial Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating omalizumab for moderate-to-severe asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 3 | Status: COMPLETED